UNSPSC 51141538: Donepezil

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C24H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8SSC91326P, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)- but generally known as donepezil, which bears US NIH Compound Identifier 3152. European Medicines Agency schedules Donepezil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06362MIG.

UNSPSC 51141538 Donepezil is a Commodity code that nominally identifies a single pharmaceutical product—donepezil, an acetylcholinesterase inhibitor used to treat Alzheimer's disease—but recent state and local procurement activity under this code shows a significant mismatch. The sole recent opportunity on record involves naloxone (an opioid overdose reversal agent) and safe drug deactivation systems, neither of which are donepezil or fall within its therapeutic class. State and local procurement offices appear to be using this code inconsistently or incorrectly when tagging pharmaceutical and medical supply procurements, suggesting that the code's nominal scope does not reliably predict actual purchasing activity at the local level.

Seminole County, Florida posted an IFB (Invitation for Bid) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The bid response deadline was July 26, 2023—a date inconsistent with the June 2026 posting, indicating a data quality issue in the source record. Vendors were required to submit electronic bids, include all shipping and delivery costs, hold appropriate insurance and drug-free workplace certifications, comply with E-Verify, and accept a two-year initial term with a one-year renewal option. The procurement was potentially FEMA-funded, introducing federal compliance overlay. This single opportunity provides minimal signal for market activity under the code; the absence of additional recent donepezil or related pharmaceutical procurements, combined with the product mismatch in the one available record, suggests this Commodity code sees little active state and local purchasing activity or is being used inconsistently by issuing bodies.